FOXO4-DRI

Mechanism of action

FOXO4-DRI is a synthetic D-amino-acid peptide developed by Peter de Keizer's laboratory at Utrecht University as a targeted senolytic — a compound designed to selectively kill senescent cells while sparing healthy cells. The molecular design exploits the specific dependence of senescent cells on the interaction between the forkhead transcription factor FOXO4 and the tumour-suppressor protein p53. In healthy cells, FOXO4 and p53 have roles in cell-cycle regulation and stress response; in senescent cells, these two proteins form a specific complex that prevents senescent-cell apoptosis and enables the persistence of senescent cells in tissues. Senescent cells contribute to age-related tissue dysfunction through secretion of the senescence-associated secretory phenotype (SASP) — pro-inflammatory cytokines, matrix-degrading enzymes, and growth factors that promote adjacent-tissue dysfunction and inflammation. The FOXO4-DRI peptide corresponds to a segment of the FOXO4 protein that mediates the FOXO4-p53 interaction. The 'DRI' designation reflects the D-amino-acid retro-inverso architecture — the peptide is synthesised with D-amino-acids in the reverse sequence order relative to the natural L-amino-acid parent. This inversion produces a peptide with three critical properties: (1) resistance to peptidase degradation (D-amino-acid peptides are essentially inert to natural peptidases that evolved for L-amino-acid substrates), producing dramatically extended in-vivo half-life; (2) preservation of the three-dimensional interaction surface with p53, since the retro-inverso construction reverses both the amino-acid handedness and the backbone direction, leaving the side-chain geometry essentially unchanged; and (3) low immunogenicity given the non-natural D-amino-acid composition. Mechanistically, FOXO4-DRI enters cells, binds p53, and displaces p53 from FOXO4. In healthy cells this displacement has minimal consequence because the FOXO4-p53 interaction is not required for viability. In senescent cells the displacement is catastrophic — free p53 translocates to the nucleus and mitochondria, activating the intrinsic apoptosis pathway and killing the senescent cell. The senolytic effect is therefore selectively targeted to cells specifically dependent on FOXO4-p53 complex maintenance for viability. Downstream physiological effects of senescent-cell clearance in aged mice have been documented in the seminal Baar et al. (Cell, 2017) publication and follow-on work. FOXO4-DRI treatment of aged mice produced improved organ function across multiple tissues (kidney, liver, brain, muscle), improved physical activity and endurance, restored fur density and quality, and increased overall healthspan (though not necessarily lifespan) markers. The effects require sustained treatment and diminish on discontinuation. The compound has been influential in the broader senolytic field alongside small-molecule senolytics (dasatinib + quercetin combination, navitoclax/ABT-263, fisetin) and other approaches. The peptide-based FOXO4-DRI has the theoretical advantage of specific target engagement versus the broader mechanism of small-molecule senolytics, though clinical translation has been more limited than for the small-molecule alternatives.

FOXO4-DRI exploits the specific dependence of senescent cells on the FOXO4-p53 protein-protein interaction for survival — displacing p53 from FOXO4 selectively triggers apoptosis in senescent but not healthy cells (Baar et al., Cell 2017). The D-retro-inverso peptide architecture confers peptidase resistance and low immunogenicity while preserving the interaction surface with p53, producing substantial healthspan improvements in aged mice.

— Notable finding

Research history

FOXO4-DRI was developed by Peter de Keizer and colleagues at Utrecht University, with the seminal characterisation published in Cell in 2017 (Baar et al.). The molecular-design rationale started from the observation that senescent cells maintain a specific FOXO4-p53 interaction that healthy cells do not require, providing a therapeutic window for selectively killing senescent cells while sparing healthy tissue. The D-retro-inverso architecture was chosen specifically to achieve the pharmacokinetic and immunogenicity properties needed for in-vivo research use — a deliberate medicinal-chemistry choice reflecting the difficulty of achieving sustained in-vivo activity with a natural L-amino-acid peptide. The Baar 2017 Cell publication was among the most influential contributions to the senolytic research field, demonstrating substantial healthspan improvements in aged mice treated with FOXO4-DRI. The paper generated substantial follow-on research, was heavily cited across the emerging longevity biotech sector, and stimulated interest in peptide-based senolytics as complements to small-molecule alternatives. The reception in the aging-research community was noteworthy for the visual impact of the aged-mouse phenotype changes documented in the paper — restored fur density and physical activity provided a striking demonstration of senescent-cell clearance benefit. Clinical development of FOXO4-DRI itself has been limited. The compound has been out-licensed to various biotech development groups over subsequent years, but formal Phase I/II clinical trials specifically of FOXO4-DRI have been limited in published disclosure. Regulatory pathway questions — including the challenge of defining registrable endpoints for a senolytic in the absence of a specific age-related indication — have contributed to the slower peptide-route translation compared to small-molecule approaches. The broader senolytic clinical-development space has advanced more through small-molecule combinations (dasatinib + quercetin has been in multiple Phase II trials in age-related conditions including diabetic kidney disease and idiopathic pulmonary fibrosis) than through the peptide route. de Keizer's group at Utrecht has continued to develop refined peptide senolytics and to publish mechanistic follow-on work. Academic groups elsewhere have pursued related approaches targeting other senescence-associated protein-protein interactions. As of 2026, FOXO4-DRI holds no marketing authorisation in any jurisdiction and remains a research compound. The senolytic research field is active and evolving; FOXO4-DRI serves as the foundational peptide-based senolytic in this space regardless of its specific clinical-development trajectory.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

FOXO4-DRI safety data derive primarily from pre-clinical work in aged mice. The pre-clinical safety record has been favourable at research doses used to demonstrate the senolytic and healthspan effects. Adverse events have been limited to injection-site reactions and modest transient effects. Baar and colleagues specifically noted preservation of healthy-tissue viability across kidney, liver, brain, and other organ systems in the aged-mouse-treatment paradigm, consistent with the selective-senolytic design intent. The D-amino-acid architecture confers essentially complete peptidase resistance and low immunogenicity — favourable pharmacokinetic and immunogenic properties versus L-amino-acid peptides. Anti-drug antibodies have not been a documented issue in the published pre-clinical work, which is expected given the non-natural amino-acid composition and the corresponding lack of natural T-cell epitope recognition. Theoretical safety concerns centre on the selective senolytic mechanism. Killing senescent cells has generally been beneficial in pre-clinical work but the broader consequences of large-scale senescent-cell clearance could theoretically produce unintended effects — some senescent cells play beneficial roles in wound healing (where senescent cells contribute to matrix remodelling), embryonic development (where senescence-like processes participate in tissue patterning), and immune surveillance contexts. Chronic dosing safety pharmacology is incompletely characterised, and the optimal dosing cadence to balance senescent-cell clearance benefit against theoretical off-target concerns remains a research question. The p53-activating mechanism theoretically requires consideration in oncology contexts. In healthy tissue p53 activation is transient and beneficial; in tumour contexts p53 activation is generally desirable but the specificity of the FOXO4-DRI mechanism to senescence-competent p53 pools may or may not translate consistently across tumour biology. Concurrent administration with genotoxic chemotherapy is theoretically interesting — the senolytic effect might clear chemotherapy-induced senescent cells and improve recovery — but has not been characterised in clinical settings. Contraindications on mechanistic grounds include pregnancy and lactation (developmental senescence contexts unclear), active wound healing (theoretical concern about premature clearance of wound-associated senescent cells), and any context where p53-pathway pharmacology overlaps with concurrent oncology treatment. No formal clinical safety data are available. Human use of FOXO4-DRI without proper clinical characterisation carries substantial uncertainty.

UK regulatory status

FOXO4-DRI is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971 and does not fall within any specific UK controlled-substance framework. Research-grade material is available from research-chemical and specialty peptide suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply for human use engages the Human Medicines Regulations 2012 — the relevant offences include supplying, offering to supply, or advertising for supply of an unauthorised medicine to a member of the public. Grey-market longevity supply channels have marketed FOXO4-DRI to individual consumers on longevity-optimisation grounds; this promotional activity falls squarely within MHRA jurisdiction over unlicensed-medicine advertising. Advertising Standards Authority (ASA) jurisdiction also engages when FOXO4-DRI is marketed for anti-aging, longevity, or specific age-related-disease indications. The ASA has taken action against unlicensed peptide promotion in analogous contexts, and longevity-industry marketing of senolytics is under increasing regulatory scrutiny. FOXO4-DRI is not currently on the WADA Prohibited List. Its senolytic mechanism does not fall within any current WADA category, though athletes should verify the current annual Prohibited List and note that unlicensed peptides carry inherent contamination-risk under the strict-liability anti-doping framework. For animal research under the Animals (Scientific Procedures) Act 1986 (ASPA), FOXO4-DRI work in vertebrates requires standard project and personal licences. Research applications in aged-rodent healthspan and chemotherapy-adjunct contexts are the principal use cases in the current UK academic-research landscape.

Frequently asked questions